Furthermore, recent evidence suggests that the use of AIs in coordination with ovarian suppression (which can be obtained through three methods, as ovariectomy, ovarian radiotherapy and drug castration) can represent a new adjuvant treatment option also for pre-menopausal women with hormone receptor-positive BC, reducing the risk of recurrence [6]. Here, NR4A1 is linked to breast cancer.